Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and ...

One of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its ...

It's been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn't look like slowing down any time soon.

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

CHICAGO -- An investigational allogeneic stem cell-derived islet-cell therapy helped almost all patients with type 1 diabetes ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

A single infusion of zimislecel, an investigational stem cell-based therapy, restored physiologic islet function and ...

Dexcom (Nasdaq:DXCM) has shared a new report highlighting access and attitudes toward type 2 diabetes in the U.S.

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...